JaguAhR is a Singapore-based joint venture with Aslan Pharmaceuticals focused on developing novel immuno-oncology therapeutics that target the aryl hydrocarbon receptor (AhR) pathway. AhR antagonists are envisioned as immune-oncology agents with potential applications in various solid tumors.
AhR, a key regulatory factor in the immune system, is activated by various ligands including kynurenine, which inhibits the immune cells from attacking cancer cells by suppressing the immune system. AhR antagonists work by inhibiting the interaction between various ligands, including kynurenine, and AhR, thus strongly activating the immune response, enabling immune cells to attack cancer cells.
As of 2023, we have successfully identified candidate compounds for preclinical research.